Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation

Inclusion Criteria:

• Standard risk GVHD patients with hematological malignancies;

• High risk GVHD patients with hematological malignancies: haplotype hematopoietic stemcell transplantation patients, donor is female or more than 30 years old;

• Well informed about this study and signed a consent form before the trial;

• Left ventricular ejection fraction (LVEF) ≧ 50%, no evidence of pericardial effusion;

• No evidence of lung infection by X-rays examination;

• Eastern cooperative oncology group (ECOG) performance status of 0 or 1, Hematopoieticcell transplantation - specific comorbidity index (HCT-CI) of 0, 1, 2;

• Normal liver and kidney function;

Exclusion Criteria:

• Reduce pretreatment dose or secondary transplantation;

• participate other clinical trials within 2 months before this study;

• Female, 1) pregnant/nursing period, or 2) have a pregnancy plan during the studyperiod, or 3) have fertility and cannot take effective contraception;

• History of severe allergic disease or is allergic to one or more drugs;

• Patients who are considered unsuitable for the study by the investigator.